The world of medicine is constantly evolving as more and more research is conducted and breakthroughs are made. One area that has been garnering a lot of attention lately is the use of psychedelics in mental health treatment. And it seems that Big Pharma is taking notice.
In this conversation, David and James discuss the great deal of work that Mindset has done to set the stage for the launch of one or more drug candidates into first in-human clinical trials in 2023.
This week in psychedelic business news: ARK Invest advances deep dive into psychedelic stocks; Cybin moves closer to clinical trials, and more!
This week in psychedelic business news: Mindset Pharma files a new patent; Ehave’s MetaHealthU app seeks to cure HPPD; Wellbeing Digital Sciences contemplates a sale.
Levitee Labs Announces Interim CEO and Board of Directors Shuffle…
The partnership with global pharmaceutical company Otsuka positions the psychedelic medicine company as a leader in the industry.
This week in psychedelic business news: A major player begins manufacturing; another rebrands; and one of the biggest gets bigger.
CEO of Mindset Pharma, James Lanthier, gives us an overview of his company and the 4 new psychedelics they are creating. He also discusses some big breaking news!
This week in psychedelic business news: Mindset Pharma partners with global pharmaceutical company; Awakn Life Sciences explores behavioral addictions; Ei.Ventures buys virtual land for psychedelic therapy.
It’s yet another sign that the pharmaceutical industry at large is taking the potential of psychedelics very seriously.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.